CDK10 has been identified as a candidate tumor suppressor in hepatobiliary cancers, including hepatocellular carcinoma (HCC) and biliary tract cancers (BTC) (31, 32, 64, 67). Here, CDK10 is linked to biliary tract neoplasm.